CN109715605A - The method for preparing carotenoid monoesters - Google Patents

The method for preparing carotenoid monoesters Download PDF

Info

Publication number
CN109715605A
CN109715605A CN201780056626.6A CN201780056626A CN109715605A CN 109715605 A CN109715605 A CN 109715605A CN 201780056626 A CN201780056626 A CN 201780056626A CN 109715605 A CN109715605 A CN 109715605A
Authority
CN
China
Prior art keywords
formula
alkyl
base
hydrogen
carbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780056626.6A
Other languages
Chinese (zh)
Other versions
CN109715605B (en
Inventor
B·舍费尔
W·西格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of CN109715605A publication Critical patent/CN109715605A/en
Application granted granted Critical
Publication of CN109715605B publication Critical patent/CN109715605B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/24—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a kind of carotenoid monoesters for preparing formula (I), the method for the stereoisomer including formula (I), wherein R1It is such as hydrogen, C1‑C20Alkyl, C2‑C20Alkenyl, C4‑C20Dialkylene, C6‑C20Trialkenyl or C8‑C20Apos, R2It is such as hydrogen or-NRaRb, wherein RaIt is such as hydrogen, C1‑C4Alkyl ,-C (O)-C1‑C3Alkyl ,-Boc or-Cbz, RbIt is such as hydrogen or C1‑C4Alkyl, R3It is such as hydrogen, X1、X2It is independently of each other CH2Or C=O comprising make wherein X1、R1、R2And R3As defined to formula (I), R4It is phenyl, tert-butyl or tolyl, and Y‑It is that (II) phosphonium salt or its stereoisomer react in the presence of alkali or latent alkali with 12 '-apocarotenals of formula (III) or its stereoisomer, wherein X for the formula of suitable counter anion2As defined to formula (I).

Description

The method for preparing carotenoid monoesters
The present invention relates to a kind of new method of carotenoid monoesters for preparing formula (I),
Wherein R1、R2、R3、X1And X2As defined herein.
Background of invention
Naturally-produced astaxanthin and luteole exists usually in the form of the monoesters of fatty acid and diester.Depending on coming Source, the type and degree of esterification of fatty acid may be different.Such as in microalgae haematococcus pluvialis (Haematococcus Pluvialis in), such as K.Holtin et al. 2009, Anal.Bioanal.Chem.395, described in 1613, astaxanthin mainly with Palmitinic acid, oleic acid, linoleic acid or linolenic monoester form exist.
Such as in US 7,291,749, US 7,723,327, EP 1 500 645 and D.Breithaupt et al. 2004, It has been reported that the synthesis of astaxanthin monoesters in J.Agricult.Food Chem.52,3870.All these synthesis are based on non-ester The acylation of encapsulated astaxanthin.But this method is along with significant drawback, because it is almost resulted in always not only contains monoesters The also mixture containing diester and usual some unreacted astaxanthins.As is generally known in the art for generating another selection of monoesters It is the partial hydrolysis of astaxanthin diester, this equally generates the mixture of the unreacted diester of monoesters, astaxanthin and usual trace.Cause This requires meticulous measure and separates monoesters from complex mixture in any case.
Summary of the invention
It prepares on a large scale it is an object of the present invention to provide a kind of according to the side of the monoesters of formula (I) being simple and efficient Method, which is derived from a variety of different acid, particularly including fatty acid and amino acid, the latter are usually N-protected.
It has been found that can be by the way that in alkali or latent alkali (cryptobase), there are the ester phosphonium salts of following formula (II) and formula (III) No esterification 12 '-apocarotenal between Wittig reaction really realize this purpose
Wherein variable R1、R2、R3、R4、Y-、X1And X2As defined herein.
Therefore, present invention firstly relates to a kind of carotenoid monoesters for preparing formula (I), the alloisomerism including formula (I) The method of body, the method includes making 12 '-apo- carrotene of the phosphonium salt of formula (II) or its stereoisomer and formula (III) Aldehyde or its stereoisomer react in the presence of alkali or latent alkali.This reaction is hereinafter also referred to as " reaction A ".
In formula (I), (II) and (III), variable X1、X2、R1、R2And R3With following meanings:
X1、X2It is identical or different and be selected from CH2And C=O；
R1Selected from hydrogen, C1-C20Alkyl, C2-C20Alkenyl, C4-C20Dialkylene, C6-C20Trialkenyl, C8-C20Tetraene Base, C10-C20- five alkenyls, C1-C4Alkoxy, wherein alkyl, alkenyl, dialkylene, trialkenyl, the apos of above-mentioned seven kinds of groups It is unsubstituted with pentaene based moiety or can be with 1,2 or 3 selected from halogen ,-OH and C1-C4The substituent group of alkoxy,
C6-C10Aryl, benzyl, phenoxy group, benzoyloxy, wherein the aryl moieties of above-mentioned four kinds of groups are not Replace or can with 1,2 or 3 be selected from halogen ,-OH, C1-C4Alkyl and C1-C4The substituent group of alkoxy,
A-COOH、A-CONH2、A-COO-(C1-C4Alkyl), and
A-NRaRb,
R2And R3It is respectively selected from hydrogen, C independently of each other1-C20Alkyl, C2-C20Alkenyl, C4-C20Dialkylene, C6-C20- three Alkenyl, C8-C20Apos, C10-C20- five alkenyls, C1-C4Alkoxy, wherein alkyl, alkenyl, the diene of above-mentioned seven kinds of groups Base, trialkenyl, apos and pentaene based moiety are unsubstituted or can be with 1,2 or 3 selected from halogen and C1-C4Alcoxyl The substituent group of base,
R2Also selected from
-COOH、-COO-(C1-C4Alkyl), and
-NRaRb, or
R1And R2It is formed together the group of formula (I-1),
Or
R1、R2And R3It is formed together the group of formula (I-2),
Or
If R2It is-NRaRb, R1With RaC can be formed together3-C4Alkane diyl,
And wherein, as long as they occur,
* refer to the tie point with the rest part of molecule in formula (I-1) and (I-2)；
RaSelected from hydrogen, C1-C4Alkyl ,-C (O) H ,-C (O)-C1-C3Alkyl, C4-C7Naphthenic base and N-protected base, such as uncle Butoxy carbonyl (- Boc) and carboxybenzyl (- Cbz),
RbSelected from hydrogen, C1-C4Alkyl ,-C (O)-C1-C3Alkyl and N-protected base, such as-Boc and-Cbz, and
RcSelected from hydrogen, C1-C19Alkyl, C2-C19Alkenyl, C4-C19Dialkylene, C6-C19Trialkenyl, C8-C19Tetraene Base, C1-C4Alkane diyl-COOH, C2-C4Alkene diyl-COOH and C2-C4Alkynes diyl-COOH,
RdIt is hydrogen or C1-C4Alkyl, and
A is selected from C1-C5Alkane diyl, C2-C5Alkene diyl and C2-C5Alkynes diyl；
In formula (II), variable R4And Y-With following meanings:
R4Selected from phenyl, tert-butyl and tolyl, and
Y-Selected from halide ion, sulfate radical, bisulfate ion, methanesulfonate, tosylate, benzene sulfonic acid root, nitrate anion and C1-C3Alkyl formate root.
In another aspect, the present invention relates to a kind of methods of phosphonium salt for preparing formula (II) comprising compound (IV) or Its stereoisomer
Wherein variable X1、R4And Y-With meaning defined herein,
It is reacted with the carboxylic acid of formula (V) or with one of its derivative
Wherein variable R1、R2And R3With meaning defined herein, and
In n=1, variable Z is selected from halogen ,-OH ,-O-C (O)-C1-C4Alkyl, and
In n=2, variable Z is O or S,
Wherein the reaction carries out in the presence of tertiary amine, and using the compound of the formula (V) of Z=OH also It carries out in the presence of an activator.This reaction is hereinafter also referred to as " reaction B ".Reacting B is also the one of parallel patent application Part.
The invention further relates to a kind of carotenoid monoesters for preparing formula (I), the sides of the stereoisomer including formula (I) Method, which comprises as the phosphonium salt or its stereoisomer for preparing formula (II) by reaction B of first step, then exist Make in second step formula (II) phosphonium salt or its stereoisomer and 12 '-apocarotenals of formula (III) or its solid it is different Structure body reacts in the presence of alkali or latent alkali.
The invention further relates to formula as defined herein, (II) phosphonium salt, condition are group-C (O) CR1R2R3It is not second Acyl group, Ethoxyacetyl base, nitrophenoxyacetyl, propiono, bytyry, valeryl, caproyl, palmityl, stearyl Or oleoyl.
Method of the invention provides the carotenoid monoesters of acquisition formula (I), for example, especially astaxanthin and luteole Monoesters simple and efficient approach.Particularly, the reaction A of method of the invention is by greatly avoiding the formation of undesired by-product (they are typically only capable to arduously remove difficulty and very much for object, especially such as carotenoid diester and no esterification carotenoid Go) and the shortcomings that avoid the method for the prior art.
Detailed description of the invention
In the present invention, general term is such as given a definition:
Prefix Cx-CyRefer to the possibility carbon atom number in concrete condition.
Term " halogen " refers to fluorine, bromine, chlorine or iodine, preferably fluorine, chlorine or bromine in each case, the especially chlorine for Z, With regard to Y-For especially bromine.
As herein and term " the C used in the Alliyl moieties of alkoxy etc.1-C20Alkyl " refers to 1 to 3 (″C1-C3Alkyl "), 1 to 4 (" C1-C4Alkyl ") or 1 to 20 (" C1-C20Alkyl ") saturated straight chain of a carbon atom or branching Alkyl.C1-C3Alkyl is methyl, ethyl, propyl or isopropyl.C1-C4In addition alkyl is butyl, 1- methyl-propyl (Zhong Ding Base), 2- methyl-propyl (isobutyl group) or 1,1- dimethyl ethyl (tert-butyl).C1-C20Alkyl in addition still such as amyl, 1- Methyl butyl, 3- methyl butyl, 2,2- dimethyl propyl, 1- ethyl propyl, 1,1- dimethyl propyl, 1,2- dimethyl propyl, Hexyl, 1- methyl amyl, 4- methyl amyl, 1,1- dimethylbutyl, 1,3- dimethylbutyl, 2,2- dimethylbutyl, 3,3- Dimethylbutyl, 1- ethyl-butyl, 2- ethyl-butyl, 1,1,2- thmethylpropyl, 1- ethyl -1- methyl-propyl, 1- ethyl -2- Methyl-propyl, heptyl, octyl, 2- ethylhexyl, nonyl, decyl, undecyl, dodecyl, tridecyl, myristyl, Pentadecyl, cetyl, heptadecyl, octadecyl, nonadecyl, eicosyl and its position isomer.
The term as used herein " C2-C20Alkenyl " refers to the list with 2 to 20 carbon atoms and double bond in any position Unsaturated straight chain or branched hydrocarbyl radical, such as vinyl, 1- acrylic, 2- acrylic, 1- methyl ethylene, 1- cyclobutenyl, 2- Cyclobutenyl, 3- cyclobutenyl, 1- methyl-1-propylene base, 2- methyl-1-propylene base, 1- methyl -2- acrylic, 2- methyl -2- propylene Base, 1- pentenyl, 3- pentenyl, 4- pentenyl, 1- methyl-1-cyclobutenyl, 3-methyl-1-butene base, 1- methyl-2-butene Base, 2- methyl-2-butene base, 2- methyl -3- cyclobutenyl, 3- methyl -3- cyclobutenyl, 1,1- dimethyl -2- acrylic, 1,2- bis- Methyl-1-propylene base, 1,2- dimethyl -2- acrylic, 1- ethyl -1- acrylic, 1- ethyl -2- acrylic, 1- hexenyl, 3- Hexenyl, 5- hexenyl, 1- methyl-1-pentene alkenyl, 3- methyl-1-pentene alkenyl, 2- methyl -2- pentenyl, 4- methyl -2- amylene Base, 1- methyl-3-pentenyl, 4- methyl-3-pentenyl, 2- methyl -4- pentenyl, 4- methyl -4- pentenyl, 1,1- diformazan Base -2- cyclobutenyl, 1,1- dimethyl -3- cyclobutenyl, 1,2- dimethyl -1- cyclobutenyl, 1,2- dimethyl -2- cyclobutenyl, 1,2- Dimethyl -3- cyclobutenyl, 1,3- dimethyl -1- cyclobutenyl, 1,3- dimethyl -2- cyclobutenyl, 1,3- dimethyl -3- cyclobutenyl, 2,2- dimethyl -3- cyclobutenyl, 2,3- dimethyl -1- cyclobutenyl, 2,3- dimethyl -2- cyclobutenyl, 2,3- dimethyl -3- butylene Base, 3,3- dimethyl -1- cyclobutenyl, 3,3- dimethyl -2- cyclobutenyl, 1- ethyl -1- cyclobutenyl, 1- ethyl -2- cyclobutenyl, 1- Ethyl -3- cyclobutenyl, 2- ethyl -1- cyclobutenyl, 2- ethyl -2- cyclobutenyl, 2- ethyl -3- cyclobutenyl, 1,1,2- trimethyl -2- Acrylic, 1- ethyl -1- methyl -2- acrylic, 1- Ethyl-2-Methyl -1- acrylic, 1- Ethyl-2-Methyl -2- acrylic, 1- hexenyl, 2- hexenyl, 3- hexenyl, 1- heptenyl, 2- heptenyl, 3- heptenyl, 1- octenyl, 2- octenyl, 3- are pungent Alkenyl, 4- octenyl and in terms of the position of double bond and configuration and possible branched type may different nonenyl line Type and branched isomer such as (8Z)-nonenyl and its mixture, in terms of the position of double bond and configuration and possible branched type May different decene base line style and branched isomer and its mixture, in the position of double bond and configuration and possible branching class The line style and branched isomer and its mixture of hendecene base that may be different in terms of type, in the position of double bond and configuration and may Branched type in terms of may different laurylene base line style and branched isomer such as (7Z)-laurylene base and its mixture, In terms of the position of double bond and configuration and possible branched type may different tridecylene base line style and branched isomer and Its mixture, in terms of the position of double bond and configuration and possible branched type may different tetradecene base line style and branching Isomers such as (7Z)-tetradecene base and (4Z)-tetradecene base and its mixture, in the position of double bond and configuration and possible branching The line style and branched isomer and its mixture of 15 alkenyls that may be different in terms of type, in the position of double bond and configuration and can The line style and branched isomer such as (7Z)-hexadecylene base, (7E)-ten six of hexadecylene base that may be different in terms of the branched type of energy Alkenyl may be different with (9E)-hexadecylene base and its mixture, in terms of the position of double bond and configuration and possible branched type 17 alkenyls line style and branched isomer and its mixture, in terms of the position of double bond and configuration and possible branched type The line style and branched isomer of octadecylene base that may be different such as (7Z)-octadecylene base and (9Z)-octadecylene base and its mixture, In terms of the position of double bond and configuration and possible branched type may different 19 alkenyls line style and branched isomer and Its mixture, and in terms of the position of double bond and configuration and possible branched type may different icosa alkene base line style and branch Change isomers such as (9Z)-icosa alkene base and (11Z)-icosa alkene base and its mixture.
The term as used herein " C4-C20Dialkylene " refers to two pairs with 4 to 20 carbon atoms and in any position The unsaturated straight chain of the two of key or branched hydrocarbyl radical, condition are the two double bonds conjugation or isolated, such as 1,3-butadiene base, 1,3- Pentadienyl, 2,4- pentadienyl, 1,4- pentadienyl, 1,3- hexadienyl, 1,4- hexadienyl, 1,5- hexadienyl, 2, 4- hexadienyl, 2,5- hexadienyl, 1,3- heptadiene base, 1,4- heptadiene base, 1,5- heptadiene base, 1,6- heptadiene base, 2,4- heptadiene base, 2,5- heptadiene base, 2,6- heptadiene base, 3,5- heptadiene base, 3,6- heptadiene base, 1,3- octadiene Base, 1,5- octadienyl, 1,7- octadienyl, 2,4- octadienyl, 2,6- octadienyl, 3,5- octadienyl, 3,7- pungent two Alkenyl, 4,6- octadienyl, 5,7- octadienyl, 1,3- nonadiene base, 1,4- nonadiene base, 1,6- nonadiene base, 1,8- nonyl Dialkylene, 2,4- nonadiene base, 2,7- nonadiene base, 3,5- nonadiene base, 4,6- nonadiene base, 5,7- nonadiene base, 6,8- Nonadiene base, 1,3- decadinene base, 1,6- decadinene base, 2,4- decadinene base, 2,8- decadinene base, 3,5- decadinene base, 4, 6- decadinene base, 5,7- decadinene base, 6,8- decadinene base, 7,9- decadinene base, 11 carbon dialkylene of 1,3-, 11 carbon of 1,8- Dialkylene, 11 carbon dialkylene of 2,4-, 11 carbon dialkylene of 2,9-, 11 carbon dialkylene of 3,5-, 11 carbon dialkylene of 4,6-, 5, 11 carbon dialkylene of 7-, 11 carbon dialkylene of 5,10-, 11 carbon dialkylene of 6,8-, 11 carbon dialkylene of 7,9-, 8,10- 11 Carbon dialkylene, 12 carbon dialkylene of 1,3-, 12 carbon dialkylene of 1,8-, 12 carbon dialkylene of 2,4-, 12 carbon dialkylene of 2,7-, 12 carbon dialkylene of 3,5-, 12 carbon dialkylene of 4,6-, 12 carbon dialkylene of 5,7-, 12 carbon dialkylene of 5,11-, 6,8- 12 Carbon dialkylene, 12 carbon dialkylene of 7,9-, 12 carbon dialkylene of 8,10-, 12 carbon dialkylene of 9,11-, 1,3- oleatridecadiene Base, 1,8- oleatridecadiene base, 2,4- oleatridecadiene base, 3,5- oleatridecadiene base, 4,6- oleatridecadiene base, 5,7- ten Three carbon dialkylenes, 5,11- oleatridecadiene base, 6,8- oleatridecadiene base, 7,9- oleatridecadiene base, 13 carbon two of 8,10- Alkenyl, 9,11- oleatridecadiene base, 10,12- oleatridecadiene base, 14 carbon dialkylene of 1,3-, 14 carbon dialkylene of 1,9-, 14 carbon dialkylene of 2,4-, 14 carbon dialkylene of 3,5-, 14 carbon dialkylene of 4,6-, 14 carbon dialkylene of 5,7-, 5,11- 14 Carbon dialkylene, 14 carbon dialkylene of 6,8-, 14 carbon dialkylene of 7,9-, 14 carbon dialkylene of 8,10-, 14 carbon diene of 9,11- Base, 14 carbon dialkylene of 10,12-, 14 carbon dialkylene of 11,13-, 1,3- pentadecane dialkylene, 1,9- pentadecane dialkylene, 2, 4- pentadecane dialkylene, 3,5- pentadecane dialkylene, 4,6- pentadecane dialkylene, 5,7- pentadecane dialkylene, 5,12- pentadecane Dialkylene, 6,8- pentadecane dialkylene, 7,9- pentadecane dialkylene, 8,10- pentadecane dialkylene, 9,11- pentadecane dialkylene, 10,12- pentadecane dialkylene, 11,13- pentadecane dialkylene, 12,14- pentadecane dialkylene and position and structure in double bond The line style and branched isomer such as (7Z, 10Z)-ten six of 16 carbon dialkylenes that may be different in terms of type and possible branched type Carbon dialkylene and (7E, 10E)-ten six carbon dialkylenes and its mixture, in the position of double bond and configuration and possible branched type Aspect may different 17 carbon dialkylenes line style and branched isomer and its mixture, in the position of double bond and configuration and can The line style and branched isomer and its mixture, the position in double bond of 18 carbon dialkylenes that may be different in terms of the branched type of energy The line style and branched isomer of 19 carbon dialkylenes that may be different in terms of setting with configuration and possible branched type and its mixing Object, and in terms of the position of double bond and configuration and possible branched type may different 20 carbon dialkylenes line style and branching Isomers and its mixture.
The term as used herein " C6-C20Trialkenyl " refers to three pairs with 6 to 20 carbon atoms and in any position The triunsaturated straight chain or branched hydrocarbyl radical of key, it is conjugation or isolated that condition, which is each pair of in these three double bonds, such as 1,3, 5- hexatriene base, 1,3,5- heptantriene base, 1,4,6- heptantriene base, 1,3,6- heptantriene base, 2,4,6- heptantriene base, 1,3,5- Sarohornene base, 1,3,6- sarohornene base, 1,3,7- sarohornene base, 1,4,6- sarohornene base, 1,4,7- sarohornene base, 1,5,7- are pungent Trialkenyl, 2,4,6- sarohornene base, 2,4,7- sarohornene base, 2,5,7- sarohornene base, 3,5,7- sarohornene base, 1,3,5- nonyl three Alkenyl, 1,3,8- nonyl trialkenyl, 2,4,6- nonyl trialkenyl, 2,4,7- nonyl trialkenyl, 3,5,7- nonyl trialkenyl, 4,6,8- nonyl triolefin Base, 1,4,7- nonyl trialkenyl, 1,3,5- last of the ten Heavenly stems trialkenyl, 1,3,8- last of the ten Heavenly stems trialkenyl, 2,4,6- last of the ten Heavenly stems trialkenyl, 2,4,9- last of the ten Heavenly stems triolefin Base, 3,5,7- last of the ten Heavenly stems trialkenyl, 4,6,8- last of the ten Heavenly stems trialkenyl, 5,7,9- last of the ten Heavenly stems trialkenyl, 2,5,7- last of the ten Heavenly stems trialkenyl, 1,6,8- last of the ten Heavenly stems triolefin Base, 2,7,9- last of the ten Heavenly stems trialkenyl, 1,4,7- last of the ten Heavenly stems trialkenyl, 2,5,9- last of the ten Heavenly stems trialkenyl, 11 carbon trialkenyl of 1,3,5-, 1,3,8- 11 Carbon trialkenyl, 11 carbon trialkenyl of 1,6,8-, 11 carbon trialkenyl of 2,4,6-, 11 carbon trialkenyl of 2,4,10-, 2,6,9- 11 Carbon trialkenyl, 11 carbon trialkenyl of 2,7,9-, 11 carbon trialkenyl of 3,5,7-, 11 carbon trialkenyl of 4,6,8-, 4,7,10- 11 Carbon trialkenyl, 11 carbon trialkenyl of 5,7,9-, 11 carbon trialkenyl of 6,8,10-, 12 carbon trialkenyl of 1,3,5-, 1,3,8- 12 Carbon trialkenyl, 12 carbon trialkenyl of 1,6,8-, 12 carbon trialkenyl of 2,4,6-, 12 carbon trialkenyl of 2,4,10-, 2,6,9- 12 Carbon trialkenyl, 12 carbon trialkenyl of 3,5,7-, 12 carbon trialkenyl of 4,6,8-, 12 carbon trialkenyl of 4,7,11-, 5,7,9- 12 Carbon trialkenyl, 12 carbon trialkenyl of 6,8,10-, 12 carbon trialkenyl of 7,9,11-, 1,3,5- tridecatriene base, 1,3,7- ten Three carbon trialkenyls, 1,8,10- tridecatriene base, 2,4,6- tridecatriene base, 2,4,10- tridecatriene base, 2,7,10- Tridecatriene base, 3,5,7- tridecatriene base, 4,6,8- tridecatriene base, 4,7,11- tridecatriene base, 5,7,9- Tridecatriene base, 6,8,10- tridecatriene base, 7,9,11- tridecatriene base, 8,10,12- tridecatriene base, 1, 14 carbon trialkenyl of 3,5-, 14 carbon trialkenyl of 1,3,9-, 14 carbon trialkenyl of 2,4,6-, 14 carbon trialkenyl of 2,4,10-, 2, 14 carbon trialkenyl of 7,10-, 14 carbon trialkenyl of 3,5,7-, 14 carbon trialkenyl of 4,6,8-, 14 carbon trialkenyl of 4,7,11-, 14 carbon trialkenyl of 5,7,9-, 14 carbon trialkenyl of 6,8,10-, 14 carbon trialkenyl of 7,9,11-, 14 carbon triolefin of 7,10,12- Base, 14 carbon trialkenyl of 8,10,12-, 14 carbon trialkenyl of 9,11,13-, 1,3,5- pentadecane trialkenyl, 1,3,11- pentadecane Trialkenyl, 2,4,6- pentadecane trialkenyl, 2,4,9- pentadecane trialkenyl, 2,9,12- pentadecane trialkenyl, 3,5,7- pentadecane Trialkenyl, 4,6,8- pentadecane trialkenyl, 4,7,10- pentadecane trialkenyl, 5,7,9- pentadecane trialkenyl, 6,8,10- 15 Carbon trialkenyl, 7,9,11- pentadecane trialkenyl, 7,10,12- pentadecane trialkenyl, 8,10,12- pentadecane trialkenyl, 9,11, 13- pentadecane trialkenyl, 10,12,14- pentadecane trialkenyl and in the position of double bond and configuration and possible branched type The line style and branched isomer such as (7Z, 10Z, 13Z)-ten six carbon trialkenyl of the possible 16 different carbon trialkenyls of aspect, (4Z, 7Z, 10Z)-ten six carbon trialkenyls, (6E, 8E, 10Z)-ten six carbon trialkenyl, (7Z, 9E, 11Z)-ten six carbon trialkenyl, (7Z, 9E, 11E)-ten six carbon trialkenyls and (7E, 9E, 11E)-ten six carbon trialkenyl and its mixture, in the position of double bond and configuration and The line style and branched isomer and its mixture of 17 carbon trialkenyls that may be different in terms of possible branched type, in double bond The line style and branched isomer of 18 carbon trialkenyls that may be different in terms of position and configuration and possible branched type and its mixed Close object, in terms of the position of double bond and configuration and possible branched type may different 19 carbon trialkenyls line style and branching Isomers and its mixture, and 20 carbon triolefins that may be different in terms of the position of double bond and configuration and possible branched type The line style and branched isomer and its mixture of base.
The term as used herein " C8-C20Apos " refer to four pairs with 8 to 20 carbon atoms and in any position The unsaturated straight chain of the four of key or branched hydrocarbyl radical, it is conjugation or isolated that condition, which is each pair of in this four double bonds, such as 1,3, 5,7- octatetraene base, 1,3,5,7- nonyl apos, 1,3,5,8- nonyl apos, 2,4,6,8- nonyl apos, 1,4,6,8- nonyl four Alkenyl, 1,3,6,8- nonyl apos, 1,3,5,7- decatetraene base, 1,3,5,9- decatetraene base, 2,4,6,8- decatetraene base, 2,4, 7,9- decatetraene base, 3,5,7,9- decatetraene base, 11 carbon apos of 1,3,5,7-, 11 carbon apos of 1,3,8,10-, 2,4, 11 carbon apos of 6,8-, 11 carbon apos of 2,4,7,10-, 11 carbon apos of 3,5,7,9-, 11 carbon four of 4,6,8,10- Alkenyl, 12 carbon apos of 1,3,5,7-, 12 carbon apos of 1,3,6,8-, 12 carbon apos of 2,4,6,8-, 2,5,8,10- 12 carbon apos, 12 carbon apos of 3,5,7,9-, 12 carbon apos of 4,6,8,10-, 12 carbon tetraene of 4,6,9,11- Base, 12 carbon apos of 5,7,9,11-, 13 carbon apos of 1,3,5,7-, 13 carbon apos of 1,3,8,10-, 2,4,6,8- 13 carbon apos, 13 carbon apos of 2,5,8,11-, 13 carbon apos of 3,5,7,9-, 13 carbon tetraene of 3,5,8,11- Base, 13 carbon apos of 4,6,8,10-, 13 carbon apos of 5,7,9,11-, 13 carbon apos of 6,8,10,12-, 1,3,5, 14 carbon apos of 7-, 14 carbon apos of 1,3,9,11-, 14 carbon apos of 2,4,6,8-, 14 carbon tetraene of 2,5,8,11- Base, 14 carbon apos of 3,5,7,9-, 14 carbon apos of 3,5,9,12-, 14 carbon apos of 4,6,8,10-, 5,7,9,11- 14 carbon apos, 14 carbon apos of 6,8,10,12-, 14 carbon apos of 7,9,11,13-, 1,3,5,7- pentadecane tetraene Base, 1,4,10,13- pentadecane apos, 2,4,6,8- pentadecane apos, 2,4,9,11- pentadecane apos, 3,5,7,9- Pentadecane apos, 3,5,8,11- pentadecane apos, 4,6,8,10- pentadecane apos, 5,7,9,11- pentadecane tetraene Base, 6,8,10,12- pentadecane apos, 7,9,11,13- pentadecane apos, 8,10,12,14- pentadecane apos, 1,3, 16 carbon apos of 5,7-, 16 carbon apos of 2,4,6,8-, 16 carbon apos of 2,6,9,12-, 16 carbon four of 3,5,7,9- Alkenyl, 16 carbon apos of 4,6,8,10-, 16 carbon apos of 5,7,9,11-, 16 carbon apos of 6,8,10,12-, 6,8, 16 carbon apos of 11,14-, 16 carbon apos of 7,9,11,13-, 16 carbon apos of 8,10,12,14-, 8,10,13,15- 16 carbon apos, 16 carbon apos of 9,11,13,15-, 1,3,5,7- aplotaxene base, 2,4,6,8- aplotaxene Base, 3,5,7,9- aplotaxene base, 4,6,8,10- aplotaxene base, 4,7,10,13- aplotaxene base, 5,7,9, 11- aplotaxene base, 6,8,10,12- aplotaxene base, 6,8,11,14- aplotaxene base, 7,9,11,13- 17 Carbon apos, 7,9,12,14- aplotaxene base, 8,10,12,14- aplotaxene base, 9,11,13,15- aplotaxene Base, 10,12,14,16- aplotaxene base and may not in terms of the position of double bond and configuration and possible branched type With stearidonic base line style and branched isomer such as (3Z, 6Z, 9Z, 12Z)-stearidonic base and its mixture, The line style and branched isomer of 19 carbon apos that may be different in terms of the position of double bond and configuration and possible branched type And its mixture, and in terms of the position of double bond and configuration and possible branched type may different Eicosatetraenoic base line Type and branched isomer and its mixture.
The term as used herein " C10-C20- five alkenyls " refer to five with 10 to 20 carbon atoms and in any position The unsaturated straight chain of the five of double bond or branched hydrocarbyl radical, it is conjugation or isolated that condition, which is each pair of in this five double bonds, such as 1, Five alkenyl of the 3,5,7,9- last of the ten Heavenly stems, 11 light dydrocarbon alkenyl of 1,3,5,7,9-, 11 light dydrocarbon alkenyl of 1,3,6,8,10-, 1,4,6,8,10- ten One light dydrocarbon alkenyl, 11 light dydrocarbon alkenyl of 2,4,6,8,10-, 1,3,5,7,9- dodecapentaene base, 12 light dydrocarbon of 1,3,6,8,10- Alkenyl, 1,4,6,9,11- dodecapentaene base, 2,4,6,8,10- dodecapentaene base, 3,5,7,9,11- dodecapentaene base, 13 light dydrocarbon alkenyl of 1,3,5,7,9-, 13 light dydrocarbon alkenyl of 1,4,7,10,12-, 13 light dydrocarbon alkenyl of 2,4,6,8,10-, 2,5, 13 light dydrocarbon alkenyl of 7,9,11-, 13 light dydrocarbon alkenyl of 3,5,7,9,11-, 13 light dydrocarbon alkenyl of 4,6,8,10,12-, 1,3,5,7, 14 light dydrocarbon alkenyl of 9-, 14 light dydrocarbon alkenyl of 1,4,7,10,13-, 14 light dydrocarbon alkenyl of 2,4,6,8,10-, 2,5,8,11,13- 14 light dydrocarbon alkenyls, 14 light dydrocarbon alkenyl of 3,5,7,9,11-, 14 light dydrocarbon alkenyl of 3,5,8,10,12-, 4,6,8,10,12- ten Four light dydrocarbon alkenyls, 14 light dydrocarbon alkenyl of 4,6,8,10,13-, 14 light dydrocarbon alkenyl of 5,7,9,11,13-, 1,3,5,7,9- pentadecane Five alkenyls, five alkenyl of 2,4,6,8,10- pentadecane, five alkenyl of 2,5,8,11,14- pentadecane, 3,5,7,9,11- pentadecane pentaene Base, five alkenyl of 3,5,8,11,14- pentadecane, five alkenyl of 4,6,8,10,12- pentadecane, 4,6,8,11,14- pentadecane pentaene Base, five alkenyl of 5,7,9,11,14- pentadecane, five alkenyl of 5,7,9,12,14- pentadecane, 6,8,10,12,14- pentadecane pentaene Base, 16 light dydrocarbon alkenyl of 1,3,5,7,9-, 16 light dydrocarbon alkenyl of 2,4,6,8,10-, 16 light dydrocarbon alkenyl of 2,5,8,11,14-, 3, 16 light dydrocarbon alkenyl of 5,7,9,11-, 16 light dydrocarbon alkenyl of 3,5,8,10,12-, 16 light dydrocarbon alkenyl of 4,6,8,10,12-, 5,7, 16 light dydrocarbon alkenyl of 9,11,13-, 16 light dydrocarbon alkenyl of 6,8,10,12,14-, 16 light dydrocarbon alkenyl of 7,9,11,13,15-, 1,3, 17 light dydrocarbon alkenyl of 5,7,9-, 17 light dydrocarbon alkenyl of 1,3,6,9,11-, 17 light dydrocarbon alkenyl of 2,4,6,8,10-, 2,4,7,10, 17 light dydrocarbon alkenyl of 14-, 17 light dydrocarbon alkenyl of 3,5,7,9,11-, 17 light dydrocarbon alkenyl of 4,6,8,10,12-, 5,7,9,11,13- 17 light dydrocarbon alkenyls, 17 light dydrocarbon alkenyl of 6,8,10,12,14-, 17 light dydrocarbon alkenyl of 6,8,11,13,15-, 7,9,11,13, 17 light dydrocarbon alkenyl of 15-, 17 light dydrocarbon alkenyl of 8,10,12,14,16- and in the position of double bond and configuration and possible branching The line style and branched isomer such as (3Z, 6Z, 9Z, 12Z, 15Z)-ten eight light dydrocarbon of 18 light dydrocarbon alkenyls that may be different in terms of type Alkenyl and its mixture, the possible 19 different light dydrocarbon alkenyls in terms of the position of double bond and configuration and possible branched type Line style and branched isomer and its mixture, and may be different in terms of the position of double bond and configuration and possible branched type The line style and branched isomer such as (5Z, 8Z, 11Z, 14Z, 17Z)-eicosapentaenoic base and its mixture of eicosapentaenoic base.
Term " C1-C4Alkoxy " refers to the straight chain or branched-alkyl comprising 1 to 4 carbon atom through oxygen atoms bond. C1-C4The example of alkoxy is methoxyl group, ethyoxyl, positive propoxy, 1- methyl ethoxy (isopropoxy), n-butoxy, 1- Methyl propoxyl group (sec-butoxy), 2- methyl propoxyl group (isobutoxy) and 1,1- dimethylethyloxy (tert-butoxy).
Term " C6-C10Aryl " is understood to be unsaturated monocycle or bicyclic hydrocarbons base at least one phenyl ring；Example Including phenyl, indanyl and naphthalene.
Term "-COO- (C1-C4Alkyl) " refer to C as defined above through carbonyl linkage to molecule rest part1-C4- Alkoxy.Example is methoxycarbonyl, ethoxy carbonyl, propoxycarbonyl, isopropoxy carbonyl, butoxy carbonyl, Zhong Ding oxygen Base carbonyl, isobutoxy carbonyl and tert-butoxycarbonyl.
Term "-C (O)-C1-C3Alkyl " refers to the C as defined above through carbonyl linkage to molecule rest part1-C3Alkane Base.Example is methyl carbonyl, ethylcarbonyl group, propyl carbonyl and Isopropylcarbonyl.
Term " C4-C7Naphthenic base " refers to the cyclic saturated hydrocarbon base comprising 4 to 7 carbon atoms.Example is cyclobutyl, ring penta Base, cyclohexyl, bicyclic [2.1.1] hexyl, suberyl, bicyclic [2.2.1] heptyl, bicyclic [3.1.1] heptyl and bicyclic [2.2.1] Heptyl.
Term " C1-C5Alkane diyl " refers to straight chain or branched hydrocarbyl radical with 1 to 5 carbon atom, such as methylene, second -1, 2- diyl, propyl- 1,3- diyl, 2- methyl propyl- 1,3- diyl, butyl- 1,3- diyl, butyl- 1,4- diyl, 2- methyl butyl- 1,4- bis- Base and amyl- 1,5- diyl.
Term " C2-C5Alkene diyl " refers to straight chain or branching unsaturated alkyl with 2 to 5 carbon atoms, such as ethylene -1, 2- diyl, propyl- 1- alkene -1,3- diyl, but-2-ene -1,4- diyl, but-1-ene -1,3- diyl and amyl- 2- alkene -1,5- diyl.
Term " C2-C5Alkynes diyl " refers to the straight chain or branched hydrocarbyl radical with 2 to 5 carbon atoms and including three keys, such as second Alkynes -1,2- diyl, propyl- 1- alkynes -1,3- diyl, butyl- 2- alkynes -1,4- diyl and amyl- 2- alkynes -1,5- diyl.
Term " N-protected base " refers to the protecting group for being suitable for protecting or close amino.About N-protected base, reference P.G.M.Wuts,″Greene′s Protective Groups in Organic Synthesis″,5th ed.John Wiley And Sons, the 2014, the 7th chapter, page 895-1194 and references cited therein.N-protected base is especially and nitrogen-atoms one The protecting group for forming carbamate types group is acted, the carbamate types group is, for example, 9- fluorene methyl carbamate (Fmoc), replace 9- fluorene methyl carbamate such as Bts-Fmoc, Dtb-Fmoc, Mio-Fmoc, Dio-Fmoc and 9- (2,7- bis- Bromine) fluorene methyl carbamate, the chloro- 3- indenyl methyl carbamate (Climoc) of 3- indenyl methyl carbamate such as 2- and Benzo [f] indenes -3- ylmethyl (Bimoc), takes 1,1- dioxo benzo [b] thiophene -2- vlmethyl formic acid esters (Bsmoc) For ethyl carbamate such as 2,2,2- trichloroethyl carbamate (Troc), 2- trimethylsilyethyl carbamic acid Ester (Teoc), (2- phenyl -2- trimethyl silyl) ethyl carbamate (Psoc), 2- chloroethyl amino formic acid esters, 2- Phenyl ethyl carbamate (hZ), 1,1- dimethyl -2,2- dibromoethyl carbamate (DB-t-Boc), 1,1- diformazan Base -2,2,2- trichloroethyl carbamate (TCBOC), 2- pyridyl-ethyl group carbamate (Pyoc), tert-butylamino first Acid esters (BOC), fluorine-containing (fluorous) BOC (FBOC), 1- and 2- adamantylamino formic acid esters (Adoc and 2-Adoc), 1- (1- adamantyl) -1- methyl ethyl carbamate (Adpoc), 1- (3,5- di-tert-butyl-phenyl) -1- methylethylamine Formic acid esters (t-Bumeoc), N- (2- valeryl amino) -1,1- dimethylethyl carbamic ester, allyl carbamate (Alloc), Benzylcarbamate (Cbz or Z) and substituted benzyl carbamate, such as 4- methoxYbenzylamino formic acid esters (Moz), 4- nitrobenzylamino formic acid esters (PNZ), 4- methyl sulfinyl Benzylcarbamate (Msz), 4- trifluoromethyl Benzylcarbamate (CTFB) and 2- menaphthyl carbamate (CNAP).Preferably Cbz and BOC.
Below with reference to formula involved in method of the invention, reaction condition and this method (I), (II), (III), (IV) The preferred embodiment of the compound of (V), especially with respect to their substituent R1、R2、R3、R4、X1、X2、Y-、Z、A、Ra、 Rb、RcAnd RdThe explanation made is not only suitable for themselves, and particularly, suitable for mutual every kind possible combination.
For formula (I), (II), (III) and (IV), the configuration of term " stereoisomer " in particular to exocyclic double bond, They can have E or Z configuration independently of each other.In formula (I), (II), (III) and (IV), full E isomer is only shown.But It is possible that one or more double bonds have Z configuration, this is not depicted in formula.In formula (I), (II), (III) and (IV), art Language " stereoisomer " be also related to respectively with X1Or X2The configuration of adjacent ring carbon atom is respectively provided with OH group or group O- CO)CR1R2R3, can have S configuration or R configuration.
As described above, the C-C double bond in the ring exterior chain of the compound of formula (I), (II), (III) and (IV) can be independent mutually Ground has E or Z configuration.Preferred embodiment group according to the present invention, in the compound of formula (I), (II), (III) and (IV) The outer C-C double bond of ring is mainly E configuration, or is especially entirely E configuration.
When implementing reaction A of the invention, the Formation keeping of the outer C-C double bond of the ring of compound (II) and (III) is substantially not Become, i.e., it is basic in the configuration of the exocyclic double bond in the product of formula (I) and the educt (educts) of each comfortable formula (II) and (III) It is identical.Therefore, the configuration of the exocyclic double bond of the product of formula (I) is in typically at least 70 moles of %, preferably at least 80 moles of %, especially At least 90 moles of %, in the degree of especially at least 98 moles % with formula (II) and the outer C- of the respective rings of the educt of (IIII) The configuration of C double bond is identical.
In addition, the exocyclic double bond of the compound of formula (I) newly formed, i.e. two based structures of octadecanonaene of compound (I) The double bond (seeing below) of partial 11 or 11 ' positions usually has main E configuration.In this respect, term " main E configuration " refers to The double bond of 11 or 11 ' positions is being greater than 50%, preferably at least 80%, especially at least 90%, especially at least 95% journey E configuration is presented on degree.
Particularly, the educt of formula (II) is used in reaction A, the outer C-C double bond of two of them ring all has E structure substantially At least 80 moles of % of type, i.e. educt (II), especially at least 90 moles of %, especially at least 95 moles of % have full E structure Type.Particularly, use the educt of formula (III) in reaction A, the outer C-C double bond of six of them ring has an E configuration substantially, i.e., from At least 80 moles of %, especially at least 90 moles of % of object (III) are analysed, especially at least 95 moles of % have full E configuration.Especially Ground can obtain wherein all nine rings using the educt of formula (II) and (III) all substantially with full E configuration in reaction A Outer C-C double bond has the product of the formula (I) of E configuration, i.e. at least 80 moles of % of product, especially at least 90 moles of % substantially, Especially at least 95 moles of % have full E configuration.
3 of each comfortable 6 member ring of the compound of formula (II), (III) and (IV) have asymmetric center and therefore can be used as The mixture of enantiomers of 3R and 3S isomers, such as racemate, or be respectively provided with formula (IIa), (IIIa), (IVa), (IIb), the form of the pure isomer of (IIIb) and (IVb) exists:
In a preferred embodiment of the invention, wherein X1And X2It is all the formula (II), (III) and (IV) of C=O Compound is main, i.e., at least 80 moles of %, preferably at least 90 moles of %, the degree of especially at least 95 moles %, as Their S isomers (IIa), (IIIa) or (IVa) exists.Similarly, according to another preferred embodiment, wherein X1And X2All It is CH2Formula (II), (III) and (IV) compound it is main, i.e., at least 80 moles of %, preferably at least 90 moles of %, especially It is that R isomers (IIa), (IIIa) or (IVa) in the degree of at least 95 moles % as them exists.
Similarly, the compound of formula (I) two 6 member ring 3 and 3 ' positions tool there are two asymmetric center and therefore can As the diastereomeric of (3R, 3 ' R)-isomers, (3R, 3 ' S)-isomers, (3S, 3 ' R)-isomers and (3S, 3 ' S)-isomers Body mixture, the mixture of enantiomers as its (3R, 3 ' S)-and (3S, 3 ' R)-isomers or its (3R, 3 ' R)-and (3S, 3 ' S it is deposited in the form of)-isomers mixture of enantiomers, or the pure isomer to be respectively provided with formula (Ia), (Ib), (Ic) and (Id) :
In a preferred embodiment of the invention, wherein X1And X2All be the formula (I) of C=O compound it is main, i.e., On at least 80 moles of %, preferably at least 90 moles of %, the degree of especially at least 95 moles %, as its S, S ' isomers (Ia) exist.Similarly, according to another preferred embodiment, wherein X1And X2It is all CH2Formula (I) compound it is main, that is, exist At least 80 moles of %, preferably at least 90 moles of % are used as its R, R ' isomers (Ia) in the degree of especially at least 95 moles % In the presence of.
Preferably, the variable R in the compound of formula (I), (II) and (V)1、R2、R3With following meanings:
R1Selected from hydrogen, C1-C20Alkyl, C2-C20Alkenyl, C4-C20Dialkylene, C6-C20Trialkenyl, C8-C20Tetraene Base, C10-C20- five alkenyls, A-COOH, A-CONH2With A-COO- (C1-C4Alkyl) and C1-C4Alkoxy, especially hydrogen, C1- C20Alkyl, C2-C20Alkenyl, C4-C20Dialkylene, C6-C20Trialkenyl, C8-C20Apos, C10-C20- five alkenyls, A- COOH、A-CONH2With A-COO- (C1-C4Alkyl), especially C1-C20Alkyl, C2-C20Alkenyl, C4-C20Dialkylene, C6- C20Trialkenyl, C8-C20Apos, A-COOH, A-CONH2With A-COO- (C1-C4Alkyl),
Wherein A is as defined above at each occurrence, and especially C1-C4Alkane diyl, especially CH2Or CH2CH2,
R2Selected from hydrogen ,-COOH ,-COO- (C1-C4Alkyl) and-NRaRb, wherein RaAnd RbWith meaning defined above, Particularly, R2It is hydrogen or-NRaRb, wherein RaAnd RbWith meaning defined above, especially there are following meanings:
RaSelected from hydrogen, C1-C4Alkyl ,-C (O)-C1-C3Alkyl and N-protected base, especially-Boc or-Cbz, and
RbIt is hydrogen or C1-C4Alkyl, or
R1And R2It can be formed together formula (I-1) or the group of (I-2), especially can only form the group of formula (I-1), especially Formula (I-1) or the group of (I-2) are not formed.Herein, RcAnd RdIn variable it is as defined above, especially have following meanings:
RcSelected from hydrogen, C1-C19Alkyl, C2-C19Alkenyl, C4-C19Dialkylene, C6-C19Trialkenyl and C8-C19Tetraene Base, especially hydrogen, C1-C19Alkyl, C2-C19Alkenyl, C4-C19Dialkylene and C6-C19Trialkenyl, especially hydrogen, C1-C17- Alkyl, C2-C17Alkenyl and C4-C17Dialkylene, and
RdIt is hydrogen or C1-C4Alkyl, especially hydrogen,
R3Selected from hydrogen, C1-C20Alkyl and C2-C20Alkenyl, especially hydrogen.
It is highly preferred that the variable R in the compound of formula (I), (II) and (V)1、R2、R3With following meanings:
R1Selected from hydrogen, C1-C18Alkyl, C2-C18Alkenyl, C4-C18Dialkylene, C6-C18Trialkenyl, C8-C18Tetraene Base, A-COOH, A-CONH2With A-COO- (C1-C4Alkyl), especially hydrogen, C1-C18Alkyl, C2-C18Alkenyl, C4-C18- two Alkenyl, C6-C18Trialkenyl, A-COOH, A-CONH2With A-COO- (C1-C4Alkyl), wherein A is as above fixed at each occurrence Justice, and especially C1-C4Alkane diyl, especially CH2Or CH2CH2,
R2It is hydrogen or-NRaRb, wherein RaAnd RbWith meaning defined above, especially there are following meanings:
RaSelected from hydrogen, C1-C4Alkyl ,-C (O)-C1-C3Alkyl and N-protected base, such as-Boc and-Cbz, especially hydrogen ,- Boc and-Cbz, and
RbIt is hydrogen or C1-C4Alkyl, especially hydrogen, and
R3It is hydrogen or C1-C20Alkyl, especially hydrogen.
Preferably, the variable X in the compound of formula (I), (II), (III) and (IV)1And X2It is independently of each other CH2Or C =O is especially CH2Or C=O, especially all C=O.
Preferably, the variable R in the compound of formula (II) and (IV)4And Y-With following meanings:
R4Selected from phenyl, tert-butyl and tolyl, especially phenyl, and
Y-Selected from halide ion, such as bromide ion or chloride ion, sulfate radical, bisulfate ion, methanesulfonate and tosylate, Especially bromide ion, chloride ion, sulfate radical and bisulfate ion, especially bromide ion.
Preferably, the variable Z in the compound of formula (V) is chlorine ,-OH or-O-C (O)-CH in the case where n=13, special It is not chlorine or-OH, is O in the case where n=2.
Preferably, in the method for the invention, any group NR in the compound of formula (II) and (V)aRbIt is tertiary amino, Or at least one group RaOr RbIt is N-protected base, it can be after the compound of formula (II) be reacted with the compound of formula (III) from formula (I) it is broken or can be broken from compound (II) after the compound of formula (IV) is reacted with the compound of formula (V) on compound.
First group of preferred embodiment according to the present invention, group-C (O) CR in formula (I), (II) and (V)1R2R3It is derivative From with 2 to 22 carbon atoms, the saturation or unsaturated fatty acid of especially 10 to 20 carbon atoms, i.e. R2And R3It is H and R1Choosing From hydrogen, C1-C20Alkyl, C2-C20Alkenyl, C4-C20Dialkylene, C6-C20Trialkenyl, C8-C20Apos, C10-C20Pentaene Base, in particular selected from C1-C18Alkyl, C2-C18Alkenyl, C4-C18Dialkylene, C6-C18Trialkenyl and C8-C18Apos, especially Selected from hydrogen, C6-C18Alkyl, C6-C18Alkenyl, C6-C18Dialkylene and C6-C18Trialkenyl.Such group-C (O) CR1R2R3's Example includes but is not limited to acetyl group, caproyl, lauroyl, myristoyl, palmityl, stearyl, mace oil Acyl group (myristoleoyl), palmitoleoyl (palmitoleoyl), oleoyl, sub-oleoyl, α-linolenyl, γ-Asia Numb acyl group and arachidonic acyl group, especially acetyl group, lauroyl, myristoyl, palmityl, oleoyl, sub- oleoyl Base, α-linolenyl, γ-linolenyl, arachidonic acyl group, especially acetyl group, lauroyl, myristoyl, palm Acyl group, oleoyl, sub-oleoyl, α-linolenyl, γ-linolenyl.In the embodiment of this specific group, formula (I) and (II) variable X in1And X2Especially all C=O.
Second group of embodiment according to the present invention, group-C (O) CR in formula (I), (II) and (V)1R2R3Derived from alpha- The a-amino acid of amino acid or N-protected, i.e. R2It is group NRaRb, wherein RaAnd RbAs defined above and wherein particularly, RaWith RbOne or both of be N-protected base respectively, such as BOC or Cbz, and another group RaAnd RbIt is hydrogen, C1-C4Alkyl ,-C (O) H ,-C (O)-C1-C3Alkyl or C4-C7Naphthenic base, especially hydrogen or C1-C4Alkyl or RaWith R1C can be formed together3-C4Alkane two Base.In this group of embodiment, R3Especially hydrogen.R1It is as defined above and in particular selected from hydrogen, unsubstituted or with OH group C1-C4Alkyl, A-CO2H、A-CONH2, wherein A is as defined above, especially CH2Or CH2CH2And benzyl unsubstituted or with OH Base.Such group-C (O) CR1R2R3Example include but is not limited to N-Boc- glycyl, N-Cbz- glycyl, flesh aminoacyl Base, N-Boc- flesh aminoacyl, N-Cbz- flesh aminoacyl, prolyl, N-Boc- prolyl, N-Cbz- prolyl, N- Boc- alanyl, N-Cbz- alanyl, N-Boc- valyl base, N-Cbz- valyl base, N-Boc- leucyl-, N- Cbz- leucyl-, N-Boc- isoleucyl-, N-Cbz- isoleucyl-, N-Boc- phenylalanyl, N-Cbz- phenyl Alanyl, N-Boc- tyrosyl-, N-Cbz- tyrosyl-, N-Boc- seryl-, N-Cbz- seryl-, N-Boc- Soviet Union Aminoacyl, N-Cbz- Threonyl, N-Boc- asparaginyl-, N-Cbz- asparaginyl-, N-Boc- glutaminyl Base, N-Cbz- glutaminyl, especially N-Boc- glycyl, N-Cbz- glycyl, N-Boc- alanyl, N- Cbz- alanyl, N-Boc- valyl base, N-Cbz- valyl base, N-Boc- leucyl-, N-Cbz- leucyl-, N- Boc- isoleucyl-, N-Cbz- isoleucyl-, N-Boc- flesh aminoacyl, N-Cbz- flesh aminoacyl, N-Boc- prolyl, N-Cbz- prolyl, especially N-Boc- glycyl and N-Boc- flesh aminoacyl and it is deprotected group accordingly.At this Variable X in the embodiment of specific group, in formula (I) and (II)1And X2Especially all C=O.
Third group preferred embodiment according to the present invention, group-C (O) CR in formula (I), (II) and (V)1R2R3It is derivative Self-saturation or unsaturated dicarboxylic or its half ester.In this group of embodiment, R2And R3It is H and R1It is group A-COOH or A- COO-C1-C4Alkyl, wherein A is as defined above and especially CH2Or CH2CH2.Such group-C (O) CR1R2R3Example include but It is not limited to succinyl group, i.e.-C (=O)-CH2CH2COOH and corresponding C1-C4Arrcostab-C (=O)-CH2CH2COO-C1-C4- Alkyl.Variable X in the embodiment of this specific group, in formula (II)1And the variable X in formula (I)1And X2Especially C= O。
Correspondingly, one of carboxylic acid of formula (V) or derivatives thereof is preferably selected from:
There are 8 to 20 C atoms, especially there is the saturation and unsaturated fatty acid of 12 to 20 C atoms, He Youqi spreads out Raw acyl halide, especially such as acid chloride,
Chloroacetic chloride, acetic anhydride,
Succinic acid, succinic anhydride, and
- N-Boc or N-Cbz protection a-amino acid, the a-amino acid be preferably selected from glycine, alanine, valine, Leucine, isoleucine, sarcosine and proline.
Reaction of the invention as described below carries out in the reaction vessel conventionally used for such reaction, and the reaction is with even Continuous, semicontinuous or batch mode carries out.In general, the specific reaction carries out under atmospheric pressure.But the reaction can also be It is carried out under reduction or raised pressure.
The reaction A for being used to prepare the method for the invention of the carotenoid monoesters of formula (I) can be considered as Wittig reaction. Implement this turn by reacting the phosphonium salt of formula (II) in the presence of alkali or latent alkali with 12 '-apocarotenals of formula (III) Change.
In one embodiment of the invention, reaction A is carried out in the presence of a base.
In another embodiment of the present invention, reaction A is carried out in the presence of latent alkali.
The suitable alkali of reaction A for method of the invention is such as alkali and alkaline earth metal ions hydroxide, such as hydrogen Lithia, sodium hydroxide, potassium hydroxide or calcium hydroxide, alkali and alkaline earth metal ions carbonate, such as lithium carbonate, potassium carbonate or carbon Sour calcium, alkali metal hydrogencarbonate, such as sodium bicarbonate, alkoxide, especially such as alkali metal C1-C5-ol salt, such as sodium methoxide, ethyl alcohol Sodium, sodium isopropylate, sodium tert-butoxide, potassium methoxide, potassium ethoxide, potassium isopropoxide or potassium tert-butoxide and amine base are preferably selected from formula (A) Tertiary amine:
NReRfRg (A)
Wherein group Re、RfAnd RgIt is respectively selected from C independently of each other1-C6Alkyl, C5-C8Naphthenic base, phenyl and by 1,2, Or 3 C1-C4Alkyl-substituted phenyl or ReAnd RfBe formed together in addition to tertiary N atom also with N atom can have selected from O, S and N-Rx(wherein RxIt is C1-C6Alkyl) saturation N- heterocycle or R as ring members of additional hetero atom or heteroatom groupe、Rf And RgIt is formed together that 8 to 12 yuan of N- are miscellaneous bicyclic, and especially 8 to 12 yuan of N- are miscellaneous bicyclic with nitrogen-atoms, wherein tertiary hetero atom is in ring A part of amidine group.Further preferred tertiary amine base is N- heteroaromatics, and wherein N atom is the ring of Aromatic moieties Atom.N- heteroaromatics is optionally selected from C by 1,2 or 31-C4Alkyl, halogen, 1- pyrrolidinyl and two (C1-C3Alkane Base) amino group replace.Suitable N- heteroaromatics is pyridine, N- (C1-C4)-alkyl imidazole and quinoline, wherein carbon is former Son is unsubstituted or with 1,2 or 3 selected from C1-C4Alkyl, halogen, 1- pyrrolidinyl and two (C1-C3Alkyl) amino Group.
The example of preferred tertiary amine includes but is not limited to three-C1- C6- alkylamine (or (C1-C6Alkyl)3N), such as trimethyl Amine, methyidiethylamine, methyl diisopropylamine and ethyl diisopropyl amine, cyclohexyldimethyl amine, cyclohexyl diethylamide, N- methyl piperidine, N-methylmorpholine, N, N- lupetazin, 1,4- diazabicyclo [2.2.2] octane (DABCO), 1,5- bis- Azabicyclo [4.3.0] nonyl- 5- alkene (DBN), 11 carbon -7- alkene (DBU) of 1,8- diazabicyclo [5.4.0], N- methylimidazole, Optionally with pyridine, 4- (dimethylamino) pyridine and 4- (the 1- pyrrolidines of 1,2 or 3 substituent group selected from methyl and ethyl Base) pyridine.
Particularly preferred alkali for reacting A is alkoxide and tertiary amine, is preferably selected from C1-C5-ol salt, such as sodium methoxide, ethyl alcohol Sodium, sodium isopropylate, potassium methoxide, potassium ethoxide or potassium isopropoxide, (C1-C6Alkyl)3N, DBU, DBN, DABCO, N- methylimidazole, appoint Pyridine, 4- (dimethylamino) pyridine and 4- (1- pyrrolidinyl) of the choosing with 1,2 or 3 substituent group selected from methyl and ethyl Pyridine.
Especially preferred alkali for reacting A is selected from sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, DBU, DABCO, N- first Base imidazoles, the pyridine optionally with 1,2 or 3 methyl, 4- (dimethylamino) pyridine and 4- (1- pyrrolidinyl) pyridine, especially Selected from DBU, DBN, DABCO, pyridine, sodium methoxide and sodium ethoxide, it is especially selected from DBU and sodium methoxide.
Latent alkali in this article refers to the attack release for passing through nucleophile with the reagent for hiding alkalinity, the alkalinity.Suitably Latent alkali is such as aliphatic series and cycloaliphatic epoxides, preferably has those of 2 to 6 carbon atoms, such as C2-C6Epoxyalkane hydrocarbon Or C5-C6Epoxy cycloalkane.Think, in mild nucleophile, as Wittig Xing phosphonium salt counter anion in the presence of, epoxides Corresponding alcoxylates can be converted to by ring-opening reaction.
Therefore, aliphatic series or cycloaliphatic epoxides presence in reaction A in latent alkali, especially for example with 2 to 6 carbon atoms In the case where lower progress, preferably there is also the formula that may originate from (anion of II) phosphonium salt, such as halide anions.Therefore, in this hair In a bright specific embodiment, reaction A is not only also carried out in the presence of halide anion in the presence of latent alkali, halogen yin from Son is preferably selected from chloride ion, bromide ion and iodide ion.In another embodiment of the present invention, reaction A exists in latent alkali Lower progress, and (counter anion of II) phosphonium salt is halide anion to formula, and halide anion is preferably selected from chloride ion, bromide ion And iodide ion.
Preferably, the latent alkali for the reaction A of method of the invention is selected from C2-C6Epoxyalkane hydrocarbon, in particular selected from epoxy Propane and 1,2- epoxy butane, especially 1,2- epoxy butane.
In a preferred embodiment of the invention, the reaction A of method of the invention is in the alkali for being selected from alkoxide and tertiary amine In the presence of carry out, the alkali for example be especially sodium methoxide, sodium ethoxide, DBU, DBN or DABCO, especially sodium methoxide or DBU.
In reaction A, formula (II) phosphonium salt and 12 '-apocarotenals of formula (III) in usual 1:1 to 3:1, It is preferred that the molar ratio reaction in the range of 1:1 to 2:1, more preferable 1.2:1 to 1.8:1, especially 1.3:1 to 1.55:1.
If using alkali in reaction A, with usual 0.5 to 2.0mol, preferably 0.5 to 1.6mol, especially 0.6 to The total amount of 1.4mol, especially 0.7 to 1.2mol use, and are based on 1 mole of formula (II) phosphonium salt in each case.Using uncle In the case that amine such as DBU are as alkali, with usual 0.8 to 2.0mol, preferably 1.0 to 1.5mol, especially 1.0 are to 1.2mol's Total amount uses, and in the case where using alkoxide such as sodium methoxide as alkali, with usual 0.5 to 1.5mol, preferably 0.6 to The total amount of 1.2mol, especially 0.7 to 1.0mol use, and are based on 1 mole of formula (II) phosphonium salt in each case.
If using latent alkali in reaction A, with usual 1.5 to 20mol, preferably 2 to 10mol, more preferable 3 to 8mol, The total amount of especially 4 to 7mol, especially 5 to 6mol use, in each case by 1 mole of formula (based on II) phosphonium salt.
The reaction of method of the invention preferably carries out in organic solvent.
It has been found that being frequently advantageous that, aprotic organic solvent, especially pole are used to the reaction A of method of the invention Property aprotic organic solvent, especially if it is carried out in the presence of a base.Aprotic organic solvent useful herein includes halogenated C1- C4Alkane, such as methylene chloride and chloroform, C1-C4Alkyl nitrile, such as acetonitrile, ether, such as with 1,2,3 or 4 oxygen atom Aliphatic C2-C10Ether, such as C1-C4Alkoxy -C1-C4Alkane, such as Anaesthetie Ether, dipropyl ether, methyl-isobutyl ether, methyl Tertbutyl ether or ethyl tert-butyl ether (ETBE), ethylene glycol dimethyl ether (glyme), diethylene glycol dimethyl ether (diglyme) He Sanyi Glycol dimethylether (triglyme), alicyclic C4-C6Ether, as tetrahydrofuran (THF), oxinane, 2- methyltetrahydrofuran, 3- methyltetrahydrofuran and Isosorbide-5-Nitrae-dioxane, aliphatic (acid) ester, such as C1-C4Alkanoic acid C1-C4Arrcostab, such as acetic acid second Ester or isopropyl acetate, aromatic hydrocarbons are such as selected from C optionally with 1 to 41-C4The benzene of the substituent group of alkyl and chlorine, such as chlorobenzene, first Benzene, dimethylbenzene and mesitylene, dimethylformamide (DMF), n-methyl-2-pyrrolidone (NMP) or these solvents with each other Mixture.
The solvent of reaction A for method of the invention is preferably selected from halogenated C1-C4Alkane, C1-C4Alkyl nitrile, C1-C4- Alkoxy -C1-C4Alkane, THF, 1,4- dioxane, C1-C4Alkanoic acid C1-C4Arrcostab, optionally with 1 to 4 Selected from C1-C4Benzene, DMF and the NMP and its mixture of the substituent group of alkyl and chlorine, in particular selected from methylene chloride, acetonitrile, methyl- tert Butyl ether, THF, 1,4- dioxane, ethyl acetate, isopropyl acetate and toluene and its mixture.
Alternatively, solvent has also selected from proton in the case where the reaction A of method of the invention is carried out in the presence of latent alkali Solvent, such as alcohol, such as C1-C6Alkanol.Preferred proton-organic solvent is selected from ethyl alcohol, propyl alcohol, isopropanol, fourth in this respect Alcohol, sec-butyl alcohol, isobutanol and the tert-butyl alcohol, especially ethyl alcohol or isopropanol.
In one embodiment of the invention, the reaction A of method of the invention in the presence of latent alkali and is being selected from polarity It is carried out in the solvent of aprotic organic solvent and proton-organic solvent, polar non-proton organic solvent is especially above as preferred Those of mention, proton-organic solvent is for example especially C1-C6Alkanol is preferably selected from C1-C4Alkanol, be more preferably selected from ethyl alcohol, Propyl alcohol and isopropanol, are especially selected from ethyl alcohol and isopropanol.
Based on 1 mole of formula (II) phosphonium salt, the solvent total amount of the reaction A for method of the invention be usually 500 to 10000 grams, preferably 1000 to 7000 grams, especially 1500 to 6000 grams.
It is preferable to use substantially anhydrous solvents, that is, have and be less than 1000ppm, be especially not more than the water content of 200ppm.
Reactant can be contacted with each other in principle with any required sequence.For example, the phosphonium salt and formula of formula (II) can be loaded at first (III) 12 '-apocarotenal (if appropriate, with dissolution or discrete form) simultaneously mutually mixes.Then gained can be mixed Object is closed to mix with alkali or latent alkali.On the contrary, the phosphonium salt (if appropriate, with dissolution or discrete form) of formula (II) can be loaded at first simultaneously It is mixed with the mixture of 12 '-apocarotenals of formula (III) and alkali or latent alkali.Alternatively, can also be by all reactants simultaneously It is added in reaction vessel.As further substitution, reactant can also be added separately in reaction vessel, preferably in the formula of addition (alkali or latent alkali are II added after) phosphonium salt.
It has been found that it is advantageous that loading phosphonium salt or its 12 '-with formula (III) of formula (II) at first in the reaction vessel The mixture of apocarotenal, such as in a dispersed form or preferably with dissolved form, the 12 '-Ahs of formula (III) are then added Plain carotenal (if applicable) then gradually or is added at one time alkali or latent alkali.12 '-apo- carrotene of formula (III) Aldehyde uses same as before or with dissolved form.It using alkali, is preferably gradually added into, and is using latent alkali, such as spy In the case where being not (cyclo) aliphatic epoxides, it is possible that disposable loading is into reaction vessel.
In general, the reaction A of method of the invention is carried out under temperature control.The reaction is usually having agitating device Closing or preferred open reaction vessel in carry out.The reaction temperature of method of the invention depends on different factors, especially depends on In alkali or latent alkali used, and can for example be determined by simple preliminary experiment in single situation by those skilled in the art. In general, the conversion of method of the invention is at -20 to 150 DEG C, preferably -10 to 120 DEG C, especially -5 to 100 DEG C of temperature Lower progress.React A in use alkali in the case where, temperature be preferably -20 to 50 DEG C, more preferably -10 to 25 DEG C, especially -5 to To 3 DEG C, and in the case where in reacting A using latent alkali, temperature is preferably 0 to 150 DEG C for 10 DEG C, especially -3, more preferable 5 to 120 DEG C, especially 10 to 100 DEG C, especially 15 to 90 DEG C.
An embodiment according to the present invention, the reaction A of method of the invention at a lower temperature, for example, if making With latent alkali, start at a temperature of 5 to 40, preferably 10 to 30 DEG C, then improve temperature to ceiling temperature, for example, if using If latent alkali, 50 to 150 DEG C are increased to, the temperature within the scope of preferably 60 to 100 DEG C.
Whether there is exhaust outlet depending on solvent for use, reaction temperature and reaction vessel, establish usual 1 during the reaction To 5 bars, preferably 1 to 3 bar of pressure.
The post-processing of the reaction mixture obtained in the reaction A of method of the invention and the carotenoid monoesters of formula (I) Separation carry out in a usual manner, such as by quenching step, then aqueous extraction is post-processed or is for example removed under reduced pressure molten Agent.Instead of removing solvent, can also be substituted waiting to hold in the way of distillation by another solvent, the product of formula (I) therefrom crystallizes.Alternatively, The organic phase obtained after aqueous extraction post-processes can be imposed etc. and to hold the way of distillation to substitute solvent, then crystallize the production of formula (I) Object.In general, obtaining the ester of formula (I) with enough purity by applying these measures or combinations thereof.Therefore, further purification step, it is special It is not complex steps, as chromatography is not usually necessary.But, if it is desired, side usually used in this field can be passed through Method implements further purification.
Preferably as the initial step of post-processing, using alkali, after the conversion was complete by preferably to anti- It answers and acid or its aqueous solution, such as acetic acid is added in mixture, be usually subsequently added into water and quench reaction A.If applicable, it then removes Water phase, organic phase are usually washed with water.Using latent alkali, such quenching step be may not be necessary.Especially make Use aliphatic series or cycloaliphatic epoxides as latent alkali in the case where, what is be usually enough to is removing solvent and such as after completion of the reaction If fruit there will be further work-up step, gained residue is redissolved or is resuspended in suitable organic solvent.
Then can will as described above by or without aqueous extraction post-process obtained by containing formula (I) product it is organic Mutually directly or in partially or completely removing solvent (if applicable) and optionally further purification step (such as column chromatography) introduce afterwards Further reaction step.Alternatively, crystallization condition can be imposed to organic phase and after the completion of crystallization, crystal, the washing of formation are separated And it is dry.It is frequently advantageous that, is crystallized in the solvent other than the solvent for the reaction.In this case, with more Solvent suitable for crystallization substitutes original solvents, such as removes by simply removing original solvents, such as under reduced pressure, and by institute Residue is re-dissolved in novel solvent, or by using equal appearance way of distillation.
It is as previously mentioned, another aspect of the present invention relates to the present invention of the carotenoid monoesters of the formula that is used to prepare (I) Method, also comprise preparation formula (II) phosphonium salt comprising make the carboxylic acid of the compound of formula (IV) and formula (V) or spread out with it One of biology reaction, wherein the reaction carries out in the presence of tertiary amine, and the feelings of the compound in the formula (V) using Z=OH It is also carried out in the presence of an activator under condition.This reaction step of B is referred to herein as reacted usually in reaction A, that is, uses formula (III) phosphonium salt of 12 '-apocarotenal conversion formula (II) carries out before the carotenoid monoesters to provide formula (I).
The suitable tertiary amines of reaction B for method of the invention are that just reaction A those of is mentioned herein.For reacting The preferred tertiary amine of B is (C1-C6Alkyl)3N, DBU, DABCO, N- methylimidazole, optionally with 1,2 or 3 be selected from methyl and second The pyridine of the substituent group of base, 4- (dimethylamino) pyridine and 4- (1- pyrrolidinyl) pyridine, especially Trimethylamine, N- methyl Imidazoles, the pyridine optionally with 1,2 or 3 methyl, 4- (dimethylamino) pyridine and 4- (1- pyrrolidinyl) pyridine, especially N- methylimidazole and pyridine.
The suitable activators of reaction B for method of the invention be essentially it is all can be by carboxylic acid (the i.e. formula of formula (V) (V) the variable Z in is-OH) it is converted to the compound of corresponding Acibenzolar or mixed anhydride, the Acibenzolar or mixed anhydride can be in uncles The alcohol of formula (IV) is converted to required formula (II) phosphonium salt ester in the presence of amine.Preferred active agent is N, N '-dicyclohexyl carbon two Imines (DCC), 1- ethyl -3- (3- dimethylaminopropyl) carbodiimide (EDC), N, N '-diisopropylcarbodiimide (DIC), the C of 1,1 '-carbonyl dimidazoles (CDI), pivalyl chloride, chloro-carbonic acid1-C3Arrcostab, phosgene, thionyl chloride and phosphinylidyne Chlorine, especially DCC, EDC and DIC.
In the reaction B of method of the invention, (one of IV) phosphonium salt and the carboxylic acid of formula (V) or derivatives thereof are logical for formula Normal 1:1 to 1:5, preferably 1:1 to 1:4, the molar ratio reaction in the range of more preferable 1:1 to 1:3, especially 1:1.1 to 1:2. Particularly, using the carboxylic acid of formula (V), i.e. Z in formula (V) is-OH, and the molar ratio of compound (IV) and (V) exist In the range of usual 1:1 to 1:2, preferably 1:1 to 1:1.5, and using the carboxylic acid derivates of formula (V), i.e. formula (V) In Z be not-OH, the molar ratio of compound (IV) and (V) are in the range of usual 1:1.2 to 1:5, preferably 1:1.5 to 1:4.
In the reaction B of method of the invention, tertiary amine is with usual 1.0 to 3.0mol, preferably 1.0 to 2.0mol, especially The amount of 1.0 to 1.5mol, especially 1.0 to 1.3mol use, in each case the carboxylic acid based on 1 mole of formula (V) or its spread out One of biology.
In the reaction B of method of the invention, if the Z that is, in formula (V) is-OH, activator using the carboxylic acid of formula (V) It is used with the amount of usual 1.0 to 2.0mol, especially 1.0 to 1.5mol, especially 1.1 to 1.3mol, in each case base In the carboxylic acid of 1 mole of formula (V).
The reaction B of method of the invention is preferably carried out in organic solvent.
It usually has been found that advantageously, the reaction B to method of the invention uses aprotic organic solvent, especially pole Property aprotic organic solvent.Aprotic organic solvent useful herein is that just reaction A those of is mentioned herein.
The solvent of reaction B for method of the invention is preferably selected from halogenated C1-C4Alkane, C1-C4Alkyl nitrile, C1-C4- Alkoxy -C1-C4Alkane, THF, 1,4- dioxane, C1-C4Alkanoic acid C1-C4Arrcostab, optionally with 1 to 4 Selected from C1-C4Benzene, DMF and the NMP of the substituent group of alkyl and chlorine, in particular selected from methylene chloride, acetonitrile, methyl tertiary butyl ether(MTBE), THF, 1,4- dioxane, ethyl acetate, isopropyl acetate and toluene.
Based on 1 mole of formula (IV) phosphonium salt, the solvent total amount of the reaction for reaction B of the invention be usually 1000 to 10000 grams, preferably 2000 to 8500 grams.
It is preferable to use substantially anhydrous solvents, that is, have and be less than 1000ppm, be especially not more than the water content of 200ppm.
The reactant of the reaction B of method of the invention can be contacted with each other in principle with any required sequence.But it sends out Now it is advantageous that loading the phosphonium salt of formula (IV) or the mixture of itself and tertiary amine at first in the reaction vessel, such as in a dispersed form Or preferably with dissolved form, tertiary amine (if applicable) then is added, then gradually or be added at one time formula (V) carboxylic acid or its spread out Biology.The carboxylic acid or derivatives thereof of formula (V) uses same as before or with dissolved form.Using activator, preferably It (before IV) phosphonium salt, later or is together loaded into reaction vessel in formula, and is only just sequentially added tertiary amine and formula hereafter (V) carboxylic acid (wherein Z=-OH).
In general, the reaction B of method of the invention is carried out under temperature control.It reacts B and is usually having agitating device Closing or preferred open reaction vessel in carry out.The reaction temperature of method of the invention depends on different factors, especially depends on The reactivity for the active ester that carboxylic acid derivates in formula used (V) or the carboxylic acid by formula (V) are formed, and can be by those skilled in the art Member is for example determined by simple preliminary experiment in single situation.In general, the conversion of method of the invention -78 to It is carried out at a temperature of 100 DEG C, preferably -20 to 80 DEG C, more preferably -10 to 60 DEG C, especially -5 to 50 DEG C.
An embodiment according to the present invention, the reaction B of method of the invention at a lower temperature, such as -10 to Start at a temperature of 40 DEG C, preferably -5 to 20 DEG C, then gradually or continuously improve temperature to ceiling temperature, such as to 0 to 80 DEG C, It is preferred that 10 to 50 DEG C of temperature.
The post-processing of the reaction mixture obtained in the reaction B of method of the invention and the formula (separation of II) phosphonium salt ester It carries out and preferably carries out as follows in a usual manner:
As the initial step of last handling process, by the way that nucleophilic chemical combination is added into reaction mixture after the conversion was complete Object, such as alcohol, such as methanol, water or diluted acid, such as the aqueous solution of acetic acid or hydrochloric acid and the reaction B for quenching method of the invention.If It is applicable in, then removes water phase, organic phase water or diluted acid, such as acetic acid or the aqueous solution extraction of hydrochloric acid, usually followed by with water The step of washing.Then can containing formula, (organic phase of II) phosphonium salt ester is directly or in partially or completely removing solvent and optionally Single step reaction step is introduced into after further purification step.Alternatively, imposing crystallization condition to organic phase and after the completion of crystallization, point Crystal, washing and drying from formation.It is frequently advantageous that, is crystallized in the solvent other than the solvent for the reaction. In this case, original solvents are substituted with the solvent for being more suitable for crystallization, such as by simply removing original solvents, such as Decompression is lower to be removed, and gained residue is re-dissolved in novel solvent, or by using equal appearance way of distillation.
As formula, ((IV) phosphonium salt can be discussed for example similar to beginning the formula of the raw material in the preparation of II) phosphonium salt The preparation of method disclosed in the prior art.Wherein X is CH2The compound of formula (IV) can for example pass through J.A.Haugan The method of 1994, Acta Chem.Scand.48,657 description passes through 3- hydroxy-beta-irisone or 3- oxo -4- hydroxy-beta - Irisone obtains corresponding tertiary C with the Grignard reaction of vinyl magnesium bromide15-ol makes itself and suitable phosphonate reagent such as hydrogen Bromic acid triphen phosphine reaction is prepared with providing the phosphonium salt of required formula (IV).Wherein X is that the compound of the formula (IV) of C=O can be with Such as pass through E.Becher et al. Helv.Chim.Acta 64 (1981), the method preparation of 2419 descriptions.
The following example is further intended to illustrate the present invention.
Embodiment
Underneath with following abbreviations:
Aq.=is aqueous
Wt-%=weight %
DCM=methylene chloride
MeOH=methanol
11 carbon -7- alkene of DBU=1,8- diazabicyclo [5.4.0]
NaOMe=sodium methoxide
EtOAc=ethyl acetate
Prepare embodiment 1:(S) -3- methyl -5- (4- palm acyloxy -2,6,6- trimethyl -3- oxo -1- cyclohexene - 1- yl)-three phenyl-bromide Phosphonium of -2,4- pentadienyl
By (S) -3- methyl -5- (4- hydroxyl -2,6,6- trimethyl -3- oxo -1- cyclohexene -1- base) -2,4- pentadiene - three phenyl-bromide Phosphonium of base (575.5 grams, 1 mole) and (2000 milliliters) of DCM 4 liters of reactors of loading and the temperature for being cooled to 0 DEG C. Be added pyridine (119.6 grams, 1512 mMs), then through 1 hour dropwise metered palmitoyl chloride (358.7 grams, 1375 mmoles You).After stirring other 18 hours at 0 DEG C, water (1000 milliliters) are added and the mixture is heated to 20 DEG C.By organic phase with Aqueous phase separation is simultaneously washed with water (1000 milliliters).The solvent of organic phase is substituted for thereafter through the distillation of the appearances such as under ambient pressure Isopropyl acetate.After 2000 milliliters of isopropyl acetates have been added, 20 DEG C at a temperature of crystal seed is added.After the completion of precipitating, The solid of formation is separated, washed with isopropyl acetate (2x400 milliliters) and is dried whole night at 20 DEG C in nitrogen stream.With 707 grams of amount obtains title compound, and the purity with 98.4 weight % is equivalent to 854.7 mMs and 85% yield.
Prepare embodiment 2:(S) -3- methyl -5- (4- oleoyl oxygroup -2,6,6- trimethyl -3- oxo -1- cyclohexene -1- Base)-three phenyl-bromide Phosphonium of -2,4- pentadienyl
Similar to preparation embodiment 1, make (S) -3- methyl -5- (4- hydroxyl -2,6,6- trimethyl -3- oxo -1- hexamethylene Alkene -1- base) -2,4- pentadienyl-three phenyl-bromide Phosphonium reacted with oleoyl chloride to provide title compound, there are > 90 weight % Purity.
Embodiment 1:(6S) -6- palm acyloxy -3- [(full E) -18- [(4S) -4- hydroxyl -2,6,6- trimethyl -3- oxygen Generation -1- cyclohexenyl group] 18 carbon -1,3,5,7,9,11,13,15,17- of -3,7,12,16- tetramethyl, nine alkenyl] -2,4,4- three Methyl-1-hexamethylene-2- ketenes ((3S, 3 ' S)-astaxanthin-monopalmitate)
By DCM (275 milliliters), (S) -3- methyl -5- (4- palm acyloxy -2,6,6- trimethyl -3- oxo -1- hexamethylene Alkene -1- base) -2,4- pentadienyl-three phenyl-bromide Phosphonium (61 grams, 75 mMs) and (S) -2,7,11- trimethyl -13- (4- hydroxyls Base -2,6,6- trimethyl -3- oxo -1- cyclohexene -1- base) (19 grams, 50 rub -2,4,6,8,10,12- ten three six alkene -1- aldehyde of carbon You) 0 DEG C at a temperature of be packed into glass reactor in succession, DBU (12.5 grams, 82,5 mMs) are then added dropwise.At 0 DEG C After continuing stirring 24 hours, acetic acid (1,5 gram, 25 mMs) is added dropwise, water (150 milliliters) are then added dropwise, and will be anti- Mixture is answered to be warming up to 20 DEG C of temperature.It is subsequently separated organic phase and water phase, the latter is extracted with (25 milliliters) of DCM.What is merged has Machine is mutually washed with water (150 milliliters), and water phase is extracted with (25 milliliters) of DCM, and combined organic phase is diluted simultaneously with (500 milliliters) of MeOH Appearances distillation is imposed etc. to substitute DCM with MeOH to gained mixture.After being cooled to 20 DEG C, crystalline solid is filtered out, filter cake is used (4x100 milliliters) of MeOH washings are simultaneously dried whole night under nitrogen stream.Title compound is obtained with 40.25 grams of amount.
Embodiment 2:(6S) -6- palm acyloxy -3- [(full E) -18- [(4S) -4- hydroxyl -2,6,6- trimethyl -3- oxygen Generation -1- cyclohexenyl group] 18 carbon -1,3,5,7,9,11,13,15,17- of -3,7,12,16- tetramethyl, nine alkenyl] -2,4,4- three Methyl-1-hexamethylene-2- ketenes ((3S, 3 ' S)-astaxanthin-monopalmitate)
By DCM (275 milliliters), (S) -3- methyl -5- (4- palm acyloxy -2,6,6- trimethyl -3- oxo -1- hexamethylene Alkene -1- base) -2,4- pentadienyl-three phenyl-bromide Phosphonium (61 grams, 75 mMs) and (S) -2,7,11- trimethyl -13- (4- hydroxyls Base -2,6,6- trimethyl -3- oxo -1- cyclohexene -1- base) (19 grams, 50 rub -2,4,6,8,10,12- ten three six alkene -1- aldehyde of carbon You) 0 DEG C at a temperature of be packed into glass reactor in succession, be then added dropwise NaOMe in MeOH solution (30 weight %, 11.25 grams, 62,5 mMs).After continuing stirring at 0 DEG C 1 hour, acetic acid (1,5 gram, 25 mMs) is added dropwise, then Water (150 milliliters) are added dropwise, and reaction mixture is warming up to 20 DEG C of temperature.It is subsequently separated organic phase and water phase, the latter It is extracted with (25 milliliters) of DCM.Combined organic phase is washed with water (150 milliliters), and water phase is extracted with (25 milliliters) of DCM.Then right Combined organic phase the appearances distillation such as imposes to substitute DCM with MeOH.After being cooled to 20 DEG C, crystalline solid is filtered out, filter cake is used (4x100 milliliters) of MeOH washings are simultaneously dried whole night under nitrogen stream.Title compound is obtained with 37.1 grams of amount.
Embodiment 3:(6S) -6- palm acyloxy -3- [(full E) -18- [(4S) -4- hydroxyl -2,6,6- trimethyl -3- oxygen Generation -1- cyclohexenyl group] 18 carbon -1,3,5,7,9,11,13,15,17- of -3,7,12,16- tetramethyl, nine alkenyl] -2,4,4- three Methyl-1-hexamethylene-2- ketenes ((3S, 3 ' S)-astaxanthin-monopalmitate)
By isopropanol (156 milliliters), (S) -3- methyl -5- (4- palm acyloxy -2,6,6- trimethyl -3- oxo -1- ring Hexene -1- base)-three phenyl-bromide Phosphonium (65.2 grams, 77.6 mMs) of -2,4- pentadienyl, (S) -2,7,11- trimethyl -13- Six alkene -1- aldehyde (19.7 of (4- hydroxyl -2,6,6- trimethyl -3- oxo -1- cyclohexene -1- base) 13 carbon of -2,4,6,8,10,12- Gram, 51.75 moles) and 1,2- epoxy butane (29.85 grams, 414 mMs) 0 DEG C at a temperature of be packed into glass reaction in succession Then device heats 16.5 hours under reflux.Then in a rotary evaporator distilling off solvent and on silica gel using hexamethylene/ EtOAc carries out column chromatography to gained residue as eluant, eluent.
Embodiment 4:(6S) -6- oleoyl oxygroup -3- [(full E) -18- [(4S) -4- hydroxyl -2,6,6- trimethyl -3- oxo - 1- cyclohexenyl group] 18 carbon 1,3,5,7,9,11,13,15,17- of -3,7,12,16- tetramethyl, nine alkenyl] -2,4,4- trimethyl - 1- hexamethylene -2- ketenes ((3S, 3 ' S)-astaxanthin-monoleate)
By isopropanol (156 milliliters), (S) -3- methyl -5- (4- oleoyl oxygroup -2,6,6- trimethyl -3- oxo -1- hexamethylene Alkene -1- base)-three phenyl-bromide Phosphonium (65.2 grams, 77.6 mMs) of -2,4- pentadienyl, (S) -2,7,11- trimethyl -13- Six alkene -1- aldehyde (19.7 of (4- hydroxyl -2,6,6- trimethyl -3- oxo -1- cyclohexene -1- base) 13 carbon of -2,4,6,8,10,12- Gram, 51.75 moles) and 1,2- epoxy butane (29.85 grams, 414 mMs) 0 DEG C at a temperature of be packed into glass reaction in succession Then device heats 16.5 hours under reflux.Then in a rotary evaporator distilling off solvent and on silica gel using hexamethylene/ EtOAc carries out column chromatography to gained residue as eluant, eluent.Title compound is obtained with 21.9 grams of amount.

Claims (18)

1. a kind of carotenoid monoesters for preparing formula (I), the method for the stereoisomer including formula (I),
Wherein
X1、X2It is identical or different and be selected from CH2And C=O；
R1Selected from hydrogen, C1-C20Alkyl, C2-C20Alkenyl, C4-C20Dialkylene, C6-C20Trialkenyl, C8-C20Apos, C10- C20- five alkenyls, C1-C4Alkoxy, wherein alkyl, alkenyl, dialkylene, trialkenyl, apos and the pentaene of above-mentioned seven kinds of groups Based moiety is unsubstituted or with 1,2 or 3 selected from halogen ,-OH and C1-C4The substituent group of alkoxy,
C6-C10Aryl, benzyl, phenoxy group, benzoyloxy, wherein the aryl moieties of above-mentioned four kinds of groups are unsubstituted Or with 1,2 or 3 be selected from halogen ,-OH, C1-C4Alkyl and C1-C4The substituent group of alkoxy,
A-COOH、A-CONH2、A-COO-(C1-C4Alkyl), and
A-NRaRb,
R2And R3It is respectively selected from hydrogen, C independently of each other1-C20Alkyl, C2-C20Alkenyl, C4-C20Dialkylene, C6-C20Triolefin Base, C8-C20Apos, C10-C20- five alkenyls, C1-C4Alkoxy, wherein the alkyl of above-mentioned seven kinds of groups, alkenyl, dialkylene, Trialkenyl, apos and pentaene based moiety are unsubstituted or with 1,2 or 3 selected from halogen and C1-C4Alkoxy Substituent group,
R2Also selected from
-COOH、-COO-(C1-C4Alkyl), and
-NRaRb, or
R1And R2It is formed together the group of formula (I-1),
Or
R1、R2And R3It is formed together the group of formula (I-2),
Or
If R2It is-NRaRb, R1With RaC can be formed together3-C4Alkane diyl,
And wherein, as long as they occur,
* refer to the tie point with the rest part of molecule in formula (I-1) and (I-2)；
RaSelected from hydrogen, C1-C4Alkyl ,-C (O) H ,-C (O)-C1-C3Alkyl, C4-C7Naphthenic base and N-protected base, such as tertiary fourth oxygen Base carbonyl (- Boc) and carboxybenzyl (- Cbz),
RbSelected from hydrogen, C1-C4Alkyl ,-C (O)-C1-C3Alkyl and N-protected base, such as-Boc and-Cbz, and
RcSelected from hydrogen, C1-C19Alkyl, C2-C19Alkenyl, C4-C19Dialkylene, C6-C19Trialkenyl, C8-C19Apos, C1- C4Alkane diyl-COOH, C2-C4Alkene diyl-COOH and C2-C4Alkynes diyl-COOH,
RdIt is hydrogen or C1-C4Alkyl, and
A is selected from C1-C5Alkane diyl, C2-C5Alkene diyl and C2-C5Alkynes diyl；
It includes the phosphonium salt or its stereoisomer for making formula (II):
Wherein X1、R1、R2And R3As defined to formula (I),
R4Selected from phenyl, tert-butyl and tolyl, and
Y-Selected from halide ion, sulfate radical, bisulfate ion, methanesulfonate, tosylate, benzene sulfonic acid root, nitrate anion and C1-C3- Alkyl formate root,
It is reacted in the presence of alkali or latent alkali with 12 '-apocarotenals of formula (III) or its stereoisomer:
Wherein X2As defined to formula (I).
2. the method according to claim 1, wherein the reaction carries out in the presence of selected from the alkali of tertiary amine and alkoxide.
3. method according to claim 2, wherein the tertiary amine is selected from (C1-C6Alkyl)3N, 11 carbon of 1,8- diazabicyclo- 7- alkene (DBU), 1,4- diazabicyclo [2.2.2] octane (DABCO), N- methylimidazole, optionally with 1,2 or 3 be selected from first Pyridine, 4- (dimethylamino) pyridine, 4- (1- pyrrolidinyl) pyridine of the substituent group of base and ethyl, and the wherein alkoxide Selected from alkali metal C1-C5-ol salt.
4. the method for any one of Claims 2 or 3, wherein alkali total amount be based on every mole of formula (II) phosphonium compounds be 0.5 to 2mol, especially 0.8 to 1.5.
5. the method for claim 1 wherein the reactions selected from aliphatic series or alicyclic epoxide with 2 to 6 carbon atoms It is carried out in the presence of the latent alkali of object.
6. method for claim 5, wherein the latent alkali reaction is in the halide anion for being selected from chloride ion, bromide ion or iodide ion In the presence of carry out.
7. the method for claim 5 or any one of 6, wherein latent alkali total amount be based on every mole of formula (II) phosphonium compounds be 1.5 to 20mol, especially 2 are to 10mol.
8. according to the method for any one of preceding claims, wherein mole of the compound of the compound of formula (II) and formula (III) Than for 1:1 to 2:1.
9., wherein the reaction carries out in aprotic solvent, being preferably selected from according to the method for any one of preceding claims C is selected from optionally with 1 to 41-C4Benzene, the C of the substituent group of alkyl and chlorine1-C4Alkoxy -C1-C4Alkane, halogenated C1-C4- Alkane, C1-C4Alkyl nitrile, dimethylformamide (DMF), n-methyl-2-pyrrolidone (NMP), tetrahydrofuran (THF), 1,4- Dioxane and C1-C4Alkanoic acid C1-C4Arrcostab and its mixture.
10. according to the method for any one of preceding claims, wherein in formula (I) and (II):
R1Selected from hydrogen, C1-C20Alkyl, C2-C20Alkenyl, C4-C20Dialkylene, C6-C20Trialkenyl, C8-C20Apos, C10- C20- five alkenyls, A-COOH, A-CONH2With A-COO- (C1-C4Alkyl), wherein A has meaning defined in claim 1,
R2It is hydrogen or-NRaRb, wherein RaAnd RbWith meaning defined in claim 1, or
R1And R2It is formed together the group of formula (I-1), wherein
RcSelected from hydrogen, C1-C19Alkyl, C2-C19Alkenyl, C4-C19Dialkylene, C6-C19Trialkenyl and C8-C19Apos, and
RdIt is hydrogen, and
R3It is hydrogen.
11. according to the method for any one of preceding claims, wherein in formula (I) and (II):
R1Selected from hydrogen, C1-C20Alkyl, C2-C20Alkenyl, C4-C20Dialkylene, C6-C20Trialkenyl, C8-C20Apos, A- COOH、A-CONH2With A-COO- (C1-C4Alkyl), wherein A is CH2Or CH2CH2；
R2It is hydrogen or-NRaRb, wherein
RaSelected from hydrogen, C1-C4Alkyl ,-C (O)-C1-C3Alkyl ,-Boc and-Cbz,
RbSelected from hydrogen and C1-C4Alkyl, and
R3It is hydrogen.
12. according to the method for any one of preceding claims, wherein structure division-C (O) CR in formula (I) or (II)1R2R3Choosing From lauroyl, myristoyl, sub-oleoyl, α-linolenyl, γ-linolenyl, succinyl group and arachidonic acyl group, Especially lauroyl and γ-linolenyl.
13. according to claim 1 to any one of 11 method, wherein structure division-C (O) CR in formula (I) or (II)1R2R3Choosing From N-Boc- glycyl, N-Cbz- glycyl, N-Boc- flesh aminoacyl and N-Cbz- flesh aminoacyl, especially N-Boc- flesh Aminoacyl.
14. further comprising the phosphonium salt for preparing formula (II) comprising formula according to the method for any one of preceding claims (IV) compound
Wherein variable X1、R4And Y-With meaning defined in claim 1,
It is reacted with the carboxylic acid of formula (V) or with one of its derivative,
Wherein
Variable R1、R2And R3With meaning defined in claim 1, and
In n=1, variable Z is selected from halogen ,-OH ,-O-C (O)-C1-C4Alkyl, and
In n=2, variable Z is O or S,
Wherein the reaction carries out in the presence of tertiary amine, and also in work using the compound of the formula (V) of Z=OH It is carried out in the presence of agent.
15. method according to claim 14, wherein the tertiary amine is selected from (C1-C6Alkyl)3N, 1,8- diazabicyclo 11 Carbon -7- alkene (DBU), N- methylimidazole, is selected from optionally with 1,2 or 3 1,4- diazabicyclo [2.2.2] octane (DABCO) Pyridine, 4- (dimethylamino) pyridine and 4- (1- pyrrolidinyl) pyridine of the substituent group of methyl and ethyl.
16. any one of 4 or 15 method according to claim 1, wherein the activator is selected from N, N '-dicyclohexylcarbodiimide (DCC), 1- ethyl -3- (3- dimethylaminopropyl) carbodiimide (EDC), N, N '-diisopropylcarbodiimide (DIC), 1, 1 '-carbonyl dimidazoles (CDI), pivalyl chloride, chloro-carbonic acid C1-C3Arrcostab, phosgene, thionyl chloride and phosphoryl chloride phosphorus oxychloride.
17. any one of 4 to 16 method according to claim 1, wherein the reaction between formula (IV) and the compound of (V) is in polarity It carries out, is preferably selected from optionally with 1 to 4 selected from C in aprotic organic solvent1-C4The benzene of the substituent group of alkyl and chlorine, C1-C4Alkoxy -C1-C4Alkane, halogenated C1-C4Alkane, C1-C4Alkyl nitrile, dimethylformamide (DMF), N- methyl -2- Pyrrolidones (NMP), tetrahydrofuran (THF), 1,4- dioxane and C1-C4Alkanoic acid C1-C4Arrcostab.
18. any one of 4 to 17 method according to claim 1, wherein the compound of formula (IV) and (V) are excellent in 1:1 to 1:3 Select the molar ratio reaction in the range of 1:1.1 to 1:2.
CN201780056626.6A 2016-09-16 2017-09-15 Process for preparing carotenoid monoesters Active CN109715605B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16189284.9 2016-09-16
EP16189284 2016-09-16
PCT/EP2017/073220 WO2018050794A1 (en) 2016-09-16 2017-09-15 Process for preparing of carotenoid mono-esters

Publications (2)

Publication Number Publication Date
CN109715605A true CN109715605A (en) 2019-05-03
CN109715605B CN109715605B (en) 2022-04-12

Family

ID=56943392

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780056626.6A Active CN109715605B (en) 2016-09-16 2017-09-15 Process for preparing carotenoid monoesters

Country Status (2)

Country Link
CN (1) CN109715605B (en)
WO (1) WO2018050794A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110431126B (en) 2017-03-20 2022-12-02 巴斯夫欧洲公司 Method for preparing bromotrichloromethane

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649839A (en) * 2002-04-30 2005-08-03 三得利株式会社 Astaxanthin medium-chain fatty acid ester, process for producing the same and composition containing the ester
WO2008023283A2 (en) * 2006-08-25 2008-02-28 Omnica Gmbh Stabilized esters of lutein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4430289A1 (en) * 1993-09-04 1995-03-09 Basf Ag Improved process for the preparation of astaxanthine
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
EP1563081A4 (en) 2002-10-25 2005-10-26 Method for producing esterified astaxanthin from esterified zeaxanthin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649839A (en) * 2002-04-30 2005-08-03 三得利株式会社 Astaxanthin medium-chain fatty acid ester, process for producing the same and composition containing the ester
WO2008023283A2 (en) * 2006-08-25 2008-02-28 Omnica Gmbh Stabilized esters of lutein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GERHARD ENGLERT ET AL.: "Synthesis, Isolation, and Full Spectroscopic Characterization of Eleven (2)-Isomers of (3R,3’R)-Zeaxanthin", 《HELVETICA CHIMICA ACT》 *
KURT BERNHARD ET AL.: "Synthese von optisch aktiven, natiirlichen Carotinoiden und strukturell verwandten Naturprodukten. IX. Synthese von (3R)-Hydroxyechinenon, (3R,3’R)- und (3R, 3’S)-Adonixanthin, (3R)-Adonirubin, deren optischen Antipoden und verwandten Verbindungen", 《HELVETICA CHIMICA ACT》 *

Also Published As

Publication number Publication date
CN109715605B (en) 2022-04-12
WO2018050794A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
JP6162795B2 (en) Lysine-glutamic acid dipeptide derivative
Yajima et al. Photoinduced radical hydroperfluoroalkylation and the synthesis of fluorinated amino acids and peptides
CN109689610A (en) The method for preparing 12 '-apocarotenal esters of the structural unit as carotenoid
US10322996B2 (en) Method for producing N-retinoylcysteic acid alkyl ester
CN109715598A (en) The method for preparing carotenoid monoesters
JP2023007949A (en) Method for removing fmoc group
CN109715605A (en) The method for preparing carotenoid monoesters
EP0338735B1 (en) Process for optically active 3-(methane-sulfonyloxy)thioland and analogs
CN109715638A (en) The method for preparing the structural unit phosphonium salt ester as carotenoid
CN110790689B (en) Synthetic method of 1, 1-difluoro-2-isonitrile-ethyl phenyl sulfone compound
ES2540211T3 (en) Process for preparing an amide of a pyrazolic carboxylic acid
CN108084073B (en) A method of purifying Bimatoprost
EP4130020A1 (en) Novel method for preparing inotodiol
KR20130046213A (en) Improved process for preparing mitiglinide calcium salt
KR101525493B1 (en) Process for preparation of high purity tamsulosin or salt thereof
US11708341B2 (en) Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof
EP3356342B1 (en) Process and intermediates for the preparation of benzo[b]thiophene compounds
EP0406567B1 (en) Process for the production of sulfonium compounds and novel methylthiophenol derivatives
IT201800006337A1 (en) LIFITEGRAST PREPARATION PROCEDURE
CN111825593B (en) Synthetic method of 3-aminopyrrole-2-formamide compound
CN118084734A (en) Preparation method of O- [2- [ [ tert-butoxycarbonyl ] amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine
Yonezawa et al. Dehydrooligopeptides. IX. Syntheses and conversions of. ALPHA.-dehydroglutamine derivatives to N-carboxy-. ALPHA.-dehydroglutamine anhydride and. DELTA. 1-dehydroglutaminyldipeptides.
CN117924154A (en) Preparation method of piperidine-2-formate compound
Shi et al. Eco-Friendly Synthesis of Sulphonic Acid Oxime Esters Catalyzed by 2-(1 H-Benzotriazole-1-yl)-1, 1, 3, 3-Tetramethyluronium Tetrafluoroborate
JPH0352854A (en) Protective reagent precursor and production thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant